ADMA Biologics Inc. (ADMA)
| Market Cap | 283.93M |
| Revenue (ttm) | 68.52M |
| Net Income (ttm) | -74.41M |
| Shares Out | 195.81M |
| EPS (ttm) | -0.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,128,963 |
| Open | 1.48 |
| Previous Close | 1.50 |
| Day's Range | 1.41 - 1.46 |
| 52-Week Range | 1.01 - 3.11 |
| Beta | 1.25 |
| Analysts | Buy |
| Price Target | 5.58 (+284.8%) |
| Earnings Date | Nov 10, 2021 |
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipel...
Financial Performance
In 2020, ADMA Biologics's revenue was $42.22 million, an increase of 43.85% compared to the previous year's $29.35 million. Losses were -$75.75 million, 56.9% more than in 2019.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ADMA Biologics stock is "Buy." The 12-month stock price forecast is 5.58, which is an increase of 284.83% from the latest price.
News
Are These Penny Stocks on Your Watchlist Right Now?
Check these penny stocks out for your watchlist The post Are These Penny Stocks on Your Watchlist Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufa...
ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC
ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Construction ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional ...
ADMA Biologics Shares Rise On Lower Than Expected Q3 Loss, Sales Double
ADMA Biologics Inc (NASDAQ: ADMA) achieved Q3 sales of $20.7 million, + 101% Y/Y, beating the consensus of $18.72 million. The increase was favorably impacted by the continued commercial ramp-up of ADMA...
Adma Biologics (ADMA) Reports Q3 Loss, Tops Revenue Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of 13.33% and 11.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments
Generated Record Total Revenues of $20.7 Million in the Third Quarter 2021, a 101% Increase Over Third Quarter 2020
Preview: ADMA Biologics's Earnings
ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors need to know before the announcement.
ADMA Biologics to Report Third Quarter 2021 Financial Results on November 10, 2021
Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET
Will Adma Biologics (ADMA) Report Negative Q3 Earnings? What You Should Know
Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters' Option to ...
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and dev...
Best Penny Stocks to Watch as The Market Turns Bullish
Penny stocks are seeing heightened momentum, which companies are you watching? The post Best Penny Stocks to Watch as The Market Turns Bullish appeared first on Penny Stocks to Buy, Picks, News and Info...
ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufa...
ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufa...
ADMA Biologics Announces Proposed Public Offering of Common Stock
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 20, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufa...
ADMA Biologics Announces a Poster Presentation at the 2021 International Society for Influenza and other Respiratory ...
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufa...
ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufa...
ADMA Biologics Announces the Presentation of Real-World Experience in the Management of Respiratory Syncytial Virus (...
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufa...
ADMA Biologics Announces Presentation on Respiratory Viral Infections at IDWeek 2021
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufa...
ADMA Biologics to Virtually Participate in the Cantor Healthcare Conference
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 23, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, ...
ADMA Biologics' Aseptic Fill-Finish Machine Scores FDA Approval
The FDA has approved ADMA Biologics Inc's (NASDAQ:ADMA) in-house aseptic fill-finish machine, the VanRx SA25. Related Content: ADMA Biologics Stock Gains On FDA Approval For Plasma Collection Facility.
ADMA Biologics to Virtually Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 02, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, ...
ADMA Biologics Stock Gains On FDA Approval For Plasma Collection Facility
The FDA has approved ADMA Biologics Inc's (NASDAQ:ADMA) BioCenters plasma collection facility in Maryville, Tennessee. The plasma collection facility commenced operations and initiated source plasma co...
ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Maryville, TN
RAMSEY, N.J. and BOCA RATON, Fla. and MARYVILLE, Tenn., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to ma...
Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of 0.00% and 7.73%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
ADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments
Achieved Record Total Revenues of $17.8 Million in Second Quarter 2021, a 129% Increase Over Second Quarter 2020